Clinical Trial

Iparomlimab and Tuvonralimab in HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single center, non-randomized, prospective phase II clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab in patients with with recurrent/metastatic head and neck squamous cell carcinoma failed second-line treatment. The participants would receive cetuximab combined with Iparomlimab and Tuvonralimab until termination criteria are met.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-21; most recent amendment 2026-06-17.
Trial Details
NCT Number NCT07090317
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2025-07-29
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18